Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors
Keywords:
Cyclin-dependent kinase inhibitor p21, Brain neoplasms, Polymorphism, genetic, Polymorphism, restriction fragment length, Blotting, westernAbstract
CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3’ untranslated region, 3’UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3’UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P > 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3’UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects.
Downloads
References
Baldwin RT, Preston-Martin S. Epidemiology of brain tumors in childhood--a review. Toxicol Appl Pharmacol. 2004;199(2):118-31.
Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci. 2001;24:385-428.
Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem. 2003;278(17):15105-15.
Kokunai T, Tamaki N. Relationship between expression of p21WAF1/CIP1 and radioresistan- ce in human gliomas. Jpn J Cancer Res. 1999;90(6):638-46.
Milner BJ, Hosking L, Sun S, Haites NE, Foulkes WD. Polymorphisms in P21CIP1/ WAF1 are not correlated with TP53 status in sporadic ovarian tumours. Eur J Cancer. 1996;32A(13):2360-3.
Viale G, Pellegrini C, Mazzarol G, Maisonneuve P, Silverman ML, Bosari S. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 muta- tions. J Pathol. 1999;187(3):302-7.
Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000;6(5):1896-9.
Jahnson S, Karlsson MG. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer. 2000;89(3): 619-29.
Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21WAF1/ CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 2000;91(1):9-15.
Facher EA, Becich, MJ, Deka A, Law JC. Association between human cancer and two poly- morphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer. 1997;79(12):2424-9.
Nadal A, Jares P, Cazorla M, et al. p21WAF1/Cip1 expression is associated with cell diffe- rentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol. 1997;183(2):156-63.
Liao WM, Zhang CL, Li FB, Zeng BF, Zeng YX. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma. Chin Med J (Engl). 2004;117(6):936-40.
Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 2000;36(1):3-7.
Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumo- ral differentiation. Oncogene. 1996;12(6):1319-24.
Souza RJSP. Estudo das alterações genéticas envolvendo o gene p21 (WAF1/CIP1/CDNK1) em meduloblastomas, ependimomas e ependimoblastomas, em menores de 18 anos. [dis- sertation]. Ribeirão Preto;. Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo;– 2003.
Mousses S, Ozçelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 1995;4(6):1089-92.
Law JC, Deka A. Identification of a PstI polymorphism in the p21Cip1/Waf1 cyclin-depen- dent kinase inhibitor gene. Hum Genet. 1995;95(4):459-60.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacterio- phage T4. Nature. 1970;227(5259):680-5.
Agresti A. Modelling patterns of agreement and disagreement. Stat Methods Med Res. 1992;1(2):201-18.
Kleinbaum J, Shamoon H. Selective counterregulatory hormone responses after oral glucose in man. J Clin Endocrinol Metab. 1982;55(4):787-90.
Koopmann J, Maintz D, Schild S, et al. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer. 1995;72(5):1230-3.
Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 1994;9(10):3021-4.
Birgander R, Själander A, Saha N, Spitsyn V, Beckman L, Beckman G. The codon 31 poly- morphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996;46(3):148-54.
Rodrigues FC, Kawasaki-Oyama RS, Fo JF, et al. Analysis of CDKN1A polymorphisms: ma- rkers of cancer susceptibility? Cancer Genet Cytogenet. 2003;142(2):92-8.
Rastinejad F, Blau HM. Genetic complementation reveals a novel regulatory role for 3’ un- translated regions in growth and differentiation. Cell. 1993;72(6):903-17.
Konishi R, Sakatani S, Kiyokane K, Suzuki K. Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors. J Dermatol Sci. 2000;24(3):177-83.
Shiohara M, el-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994:84(11):3781-4.
Jung JM, Bruner JM, Ruan S, et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene. 1995;11(10):2021-8.
Rajaraman P, Wang SS, Rothman N, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1655-61.